Management of Acquired Resistance to EGFR TKI-Targeted Therapy in Advanced Non–Small Cell Lung Cancer

Activating mutations of epidermal growth factor receptor (EGFR) in non–small cell lung cancer (NSCLC) are a favorable predictive factor for EGFR tyrosine kinase inhibitors (TKIs) treatment. However, different mechanisms of acquired resistance to first-generation and second-generation EGFR TKIs have been reported. Understanding and clarifying the biology of the resistance mechanisms of EGFR-mutant NSCLC could guide future drug development, leading to more precise therapy and advances in treatment.